2119results about "Recombinant DNA-technology" patented technology

Among other things, the present disclosure provides oligonucleotide compositions and methods thereof. In some embodiments, oligonucleotides comprise various chemical modifications. In some embodiments, the present disclosure provides technologies useful for manufacturing oligonucleotides.

The invention provides a novel goose parvovirus attenuated strain as well as a construction method and application thereof, and belongs to the field of viral vaccines. Two artificial attenuating sites capable of weakening the virulence of the novel goose parvovirus are determined through research, the live vaccine prepared by taking the obtained NGPV-NMG50 attenuated strain as an immunogen does not need to add adjuvants, the defeathering protection rate of a duck group can reach 100%, the minimum lethal dose of the virus is determined by carrying out multiple dilution on an NMG21 wild strain, and the vaccine can be used for preparing the novel goose parvovirus by taking the NGPV-NMG50 attenuated strain as an immunogen. The optimal immune dose of the NGPV-NMG50 attenuated strain is screened, so that the optimal immune dose result of the NGPV-NMG50 attenuated strain in clinical use is obtained, and an immune barrier for the novel goose parvovirus is effectively established for the ducklings.

The problem addressed by the present invention is to provide a method for detecting undifferentiated pluripotent stem cells and a reagent for detection by measuring the amount of RNA expressed by MIR302CHG gene to enable detection of a small amount of remaining undifferentiated pluripotent stem cells.

An human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human proprotein convertase subtilisin / kexin type 9 (hPCSK9) characterized by the ability to reduce serum LDL cholesterol by 40-80% over a 24, 60 or 90 day period relative to predose levels, with little or no reduction in serum HDL cholesterol and / or with little or no measurable effect on liver function, as determined by ALT and AST measurements.

To provide an electrochemiluminescent nanoprobe with a wider detection range and high sensitivity.SOLUTION: A method for producing an electrochemiluminescent nanoprobe according to an embodiment includes: a hot exciton nanoparticle synthesis step for polymerizing hot exciton organic luminescent molecules and copolymer molecules to synthesize hot exciton nanoparticles; and a hot exciton nanoparticle modification step for using oligonucleotide strands with quencher molecule modifications to modify the obtained hot exciton nanoparticles, resulting in modified hot exciton nanoparticles.SELECTED DRAWING: Figure 1

To provide a PCR reaction container free from problems associated with residual sample droplets.SOLUTION: A PCR reaction container includes a substrate, a flow channel formed in the substrate, a pair of filters provided at both ends of the flow channel, a pair of air communication ports communicating with the flow channel through the filters, a thermal cycle region formed between the pair of filters in the flow channel, and a sample injection port through which a sample can be injected into the flow channel from above, wherein the sample injection port in the surface of the substrate has an area of 0.7 to 1.8 mm2.SELECTED DRAWING: Figure 1

An improved method of treating cancers with engineered T cells is described.

Analyze gene mutations including missense mutations and / or nonsense mutations and silent mutations with high precision. 【Solution means】Detect signals from a first probe corresponding to a missense mutation or nonsense mutation in a gene mutation, a second probe corresponding to a silent mutation in the gene mutation, and a wild-type probe corresponding to the wild type, and determine the signal from the second probe as the wild type in the gene mutation.

To provide a method, a composition, and a kit for predicting the onset of moyamoya disease in a subject carrying a genetic mutation responsible for moyamoya disease.SOLUTION: Disclosed herein is a method for predicting the onset of moyamoya disease, the method including measuring the expression level of GATA2 in a sample derived from a subject carrying the p.R4810K mutation in the RNF213 gene. Also disclosed is a composition or a kit for predicting the onset of moyamoya disease in a subject carrying the p.R4810K mutation in the RNF213 gene, the composition or kit including a reagent for measuring the expression level of GATA2.SELECTED DRAWING: None

The present invention addresses the problem of providing: a Tobamovirus genus virus-resistant tomato that has a property of inhibiting infection of viruses belonging to the genus Tobamovirus, a property of suppressing proliferation of viruses belonging to the genus Tobamovirus after being infected, and / or a property of suppressing onset of symptoms caused by infection of viruses belonging to the genus Tobamovirus; tomato cells; and a method for producing the same. The problem is solved by providing a tomato which has a mutation in at least one gene selected from the group consisting of receptor-like kinase (RLK) genes and homologous genes thereof, and in which, by having said mutation, expression of the mutated gene is suppressed or a protein encoded by the mutated gene is not functional with respect to viruses belonging to the genus Tobamovirus and which is thereby resistant to viruses belonging to the genus Tobamovirus.

The present inventors have successfully prepared a library consisting essentially of a plurality of antigen-binding molecules differing in sequence from each other, the antigen-binding molecules each comprising an antibody variable region that has binding activity against a first antigen and a second antigen different from the first antigen, but does not bind to the first antigen and the second antigen at the same time. Use of the library of the present invention allows the obtainment of a variable region having enhanced ability to bind to the first antigen and the production of a bispecific antibody against the first antigen and a cancer antigen. Moreover, the present inventors have also successfully prepared an antigen-binding molecule comprising an antibody variable region that has binding activity against three different antigens, but does not bind to these antigens at the same time.

The present invention relates to a novel process for preparing compounds of formula (I) and pharmaceutically acceptable salts thereof which act as ferroportin inhibitors suitable for use as pharmaceuticals in the prevention and / or treatment of diseases caused by a deficiency of hepcidin or of disorders of iron metabolism leading to increased iron levels or increased iron absorption, including iron overload, thalassemia, sickle cell disease and hemochromatosis. JPEG2023533889000140.jpg34103

Disclosed herein are methods, compositions, and devices for use in early detection of cancer. The methods include sequencing a panel of regions in cell-free nucleic acid molecules and detecting one or more tumor markers that are indicative of a cancer.

The invention provides a method of inducing a DNA-encoded library (DEL) comprising cleavable site(s) in the DNA strand to a cross linker-modified double-stranded DEL and evaluating the DEL. Both the merits of the hairpin-stranded DEL and the double-stranded DEL are achieved in the invention by introducing the cleavable site(s) such as deoxyuridine into the DNA strand. The invention further provides a technique for screening a compound in which both “simple DEL synthesis method” and “expansion and improvement of the DEL evaluation method” are achieved by easily inducing the compound into a cross linker-modified DEL.

To provide high sensitivity and reliable data when performing PCR at high speed.SOLUTION: While applying thermal cycles at high speed reduces amplification efficiency and detection sensitivity, performing multiple thermal cycles to maximize an amount of amplified products in a short time also increases an amount of non-specific amplified products, causing a decrease in S / N and false positives, reducing the reliability of analysis results. For this reason, by changing the thermal cycle midway, it is possible to increase an amount of target products amplified at high speed and suppress non-specific amplification. More specifically, this disclosure proposes a nucleic acid amplification technique that includes a first phase in which a denaturation reaction is performed on a sample solution for a seconds, followed by an annealing and extension reaction for b seconds, and a second phase (b≠d) in which a denaturation reaction is performed on the sample solution after a first phase process is performed, for c seconds, followed by an annealing and extension reaction for d seconds.SELECTED DRAWING: Figure 2

Provided is a method with which it is possible to simply and exponentially amplify circular DNA, particularly long-chain circular DNA, in a cell-free system. Specifically, provided is a method for amplifying circular DNA, which comprises an isothermal reaction of a reaction mixture produced by mixing circular DNA having a replication initiation sequence (oriC) with a reaction solution containing the following enzyme groups: (1) a first enzyme group that catalyzes replication of the circular DNA, (2) a second enzyme group that catalyzes replication of the circular DNA, (3) a third enzyme group that catalyzes replication of the circular DNA, (4) a fourth enzyme group that catalyzes replication of the circular DNA, and (5) a third enzyme group that catalyzes replication of the circular DNA. (2) a second enzyme group which catalyzes a linking reaction of an okazaki fragment to synthesize two sister circular DNAs forming a catenary body; and (3) a third enzyme group that catalyzes a separation reaction of the two sister circular DNAs.

The present disclosure relates, at least in part, to methods and cells useful for promoting ubiquitination-independent protein degradation and for promoting protein stability using an engineered midnolin protein.

Provided herein are methods for determining allele-specific telomere length (ATL) and telomere variant repeat (TVR) sequences from long read sequencing data. In some embodiments, the methods include clustering telomere reads together into individual alleles using their adjacent TVR regions from which allele-specific TL can then be determined.

The present invention relates to anti-PD-L1 antibodies, bispecific antibodies containing one domain with specificity to PD-L1, and to immunocytokines comprising an anti-PD-L1 antibody fused to a cytokine, such as IL-2. The present invention also provides methods of treatment, uses and pharmaceutical compositions comprising the antibodies, bispecific antibodies and immunocytokines.

The disclosure relates, inter alia, to a library of transcriptional data, and methods for assembling and using same.

To identify gene mutations in MYD88 and / or CD79B simultaneously.SOLUTION: The present invention comprises: a primer set for MYD88 gene mutations, and a primer set for CD79B gene mutations; as well as a mutant-type probe for MYD88 gene, a wild-type probe for MYD88 gene, a mutant-type probe for CD79B gene, and a wild-type probe for CD79B gene.SELECTED DRAWING: None

An anti-BDCA-2 antibody or an antigen-binding fragment thereof. Also provided are a composition comprising the anti-BDCA-2 antibody or the antigen-binding fragment thereof, a nucleic acid encoding the anti-BDCA-2 antibody or the antigen-binding fragment thereof, a vector comprising the nucleic acid, and a host cell. Also provided are a therapeutic use of the anti-BDCA-2 antibody or the antigen-binding fragment thereof and a pharmaceutical composition comprising same.

To provide methods of producing hexoses from saccharides by improved enzymatic processes.SOLUTION: Methods of producing hexoses from saccharides by improved enzymatic processes are disclosed herein. The improved processes utilize enzymes with higher activities than those previously reported to convert starch or a starch derivative, cellulose or a cellulose derivative, or sucrose to a glucose 6-phosphate (G6P) intermediate.SELECTED DRAWING: Figure 2

Provided is a cell culture substrate comprising a substrate and a layer that covers at least a portion of the surface of the substrate, has a layer thickness of 5 to 2000 nm and contains a hydrophilic polymer, in which the hydrophilic polymer contains a phosphorylcholine group or a hydroxyl group, the cell culture substrate has a region (A) and a region (B) as mentioned below, and the bump height in a boundary region between the region (A) and the region (B) is 1 to 500 nm. (A) An island-like region which has cell adhesiveness and cell proliferating properties and has an area of 0.001 to 5 mm2. (B) A region which is located adjacent to the region (A) and does not have cell adhesiveness or cell proliferating properties.

To provide methods of treating a human subject having non-neurological manifestations of acid sphingomyelinase deficiency (ASMD), and in certain embodiments, NPD subtype B.SOLUTION: A method for treating a human subject having an acid sphingomyelinase deficiency comprises: (a) a regimen for debulking an accumulated sphingomyelin substrate in the human subject including (i) administering an initial low non-toxic dose of an acid sphingomyelinase (ASM) to the human subject, and (ii) administering successively higher doses of ASM to the human subject and monitoring the subject for one or more adverse side effects after each successive dose as indicated by elevated bilirubin or a related adverse event; and (b) a maintenance regimen comprising administering a dose equal to or less than the highest dose tolerated by the subject as a maintenance dose for the subject.SELECTED DRAWING: None

Described herein are serum-free and feeder-free methods and compositions for the tunable differentiation and production of CD4+ (single positive) T cells and CD8+ (single positive) T cells, by adjusting T cell receptor (TCR) stimulation and notch activation (or notch signaling activation, stimulation or inducement). In some other aspects the invention provides a method and in vitro niche and cell culture media that results in enhancing CD4+ (SP) T cell generation, including naive mature CD4+ single positive T cells from double positive (DP) CD4+8+cells or CD8+(SP) T cells by TCR stimulation while having low or no notch signaling activation, stimulation or inducement. In yet other aspects, the invention provides a method, niche and culture media for producing cells derived from CD4+ (SP) T cells, including Treg cells.

This invention provides antibodies or functional antibody fragments or probes thereof targeting a unique set of antigens recognized in cancer. The invention comprises a nucleotide sequence derived from the L2A5 monoclonal antibody. The antibodies or functional antibody fragments or probes thereof include variable heavy chain domains and variable light chain domains having the amino acid sequences provided herein. The DNA / amino acid sequence binding is unique and has never been previously described. The invention further provides antibodies or functional antibody fragments or conjugates or recombinant proteins useful for the detection, treatment, and prevention of human diseases, including cancer.

Provided are nucleic acid molecules encoding mutant Seneca Valley Virus (SVV) that evade neutralizing antibodies with a binding specificity to SVV, as well as nanoparticles containing rapamycin and SVV or mutant SVV. The mutant SVV comprise one or more mutations in one or more SVV epitopes that prevent binding of the mutant SVV to the neutralizing antibodies. The one or more mutations of the mutant SVV may be in one or more SVV epitopes. The epitopes may be inVP1, VP2, and / or VP3 subunits of SVV. Also provided are methods of producing and using the mutant SVV for treating cancer. Also provided are methods of treating a subject comprising administering to the subject the nanoparticles comprising SVV, or mutant SVV, and rapamycin. Also provided are methods of treating a subject comprising administering to the subject SVV or mutant SVV, and cyclophosphamide.

Described herein are small molecule splicing regulator compounds that regulate the splicing of mRNA, such as pre-mRNA, encoded by a gene, pharmaceutical compositions comprising the same, and methods of using the small molecule splicing regulator compounds to regulate splicing and treat diseases and conditions.

Some embodiments of the methods and compositions disclosed herein relate to immune cells that have been engineered to express chimeric antigen receptors and / or genetically modified to increase one or more aspects of the effectiveness of the immune cells in cellular immunotherapy. Some embodiments relate to genetic modifications that reduce potential side effects of cellular immunotherapy. In some embodiments, a combination of cells is used to achieve rapid and long-term tumor reduction with reduced or eliminated potential for graft-versus-host effects.